A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Durvalumab (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 20 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Mar 2017 Planned number of patients changed from 22 to 25.